Scarica l'app Stockscreener
0.8257
4.02%
-0.0346
Dopo l'orario di chiusura:
.84
0.0143
+1.73%
Precedente Chiudi:
$0.8603
Aprire:
$0.86
Volume 24 ore:
576.92K
Relative Volume:
0.26
Capitalizzazione di mercato:
$56.73M
Reddito:
$3.67M
Utile/perdita netta:
$-13.83M
Rapporto P/E:
-2.9489
EPS:
-0.28
Flusso di cassa netto:
$-10.79M
1 W Prestazione:
-14.37%
1M Prestazione:
-19.05%
6M Prestazione:
-27.57%
1 anno Prestazione:
+52.79%
Intervallo 1D:
$0.821
$0.87
Intervallo di 1 settimana:
$0.79
$0.982
Portata 52W:
$0.5101
$1.66
Icecure Medical Ltd Stock (ICCM) Company Profile
Nome
Icecure Medical Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Confronta ICCM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ICCM
Icecure Medical Ltd
|
0.8257 | 58.23M | 3.67M | -13.83M | -10.79M | -0.28 |
|
ABT
Abbott Laboratories
|
127.63 | 231.95B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
97.78 | 142.60B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
369.25 | 141.45B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
95.04 | 123.83B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
72.65 | 43.07B | 5.69B | 1.41B | 577.90M | 6.9828 |
Icecure Medical Ltd Borsa (ICCM) Ultime notizie
Why IceCure Medical Ltd stock is considered a top pick2025 Trade Ideas & Free Accurate Trade Setup Notifications - newser.com
Can swing trading help recover from IceCure Medical Ltd losses2025 Earnings Surprises & Daily Stock Trend Reports - newser.com
Comparing IceCure Medical Ltd in custom built stock radarsEarnings Overview Summary & Low Risk High Reward Ideas - newser.com
Can a trend reversal in IceCure Medical Ltd lead to recovery2025 Price Targets & Free Long-Term Investment Growth Plans - newser.com
How moving averages guide IceCure Medical Ltd tradingJuly 2025 Price Swings & Community Trade Idea Sharing Platform - newser.com
Does IceCure Medical Ltd fit your quant trading modelJuly 2025 Market Mood & Breakout Confirmation Alerts - newser.com
What momentum indicators show for IceCure Medical Ltd stock2025 Trade Ideas & Real-Time Stock Price Movement Reports - newser.com
IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances - StreetInsider
ProSense® FDA authorization: IceCure gains U.S. marketing OK for low‑risk breast cancer in patients ≥70 - Stock Titan
Investors push IceCure Medical (NASDAQ:ICCM) 13% lower this week, company's increasing losses might be to blame - simplywall.st
Pattern recognition hints at IceCure Medical Ltd upsideNew Guidance & Free Accurate Trade Setup Notifications - newser.com
New FDA-Approved Breast Cancer Treatment Freezes Tumors Instead Of Removing Them - essence.com
Brookline Capital Management Predicts IceCure Medical Q3 Earnings - MarketBeat
IceCure Medical to Attend the 2025 Maxim Growth Summit - GuruFocus
2025-10-09 | IceCure Medical to Attend the 2025 Maxim Growth Summit | NDAQ:ICCM | Press Release - Stockhouse
IceCure Medical (NASDAQ:ICCM) Given Sell (E+) Rating at Weiss Ratings - MarketBeat
IceCure Medical : Company Presentation - MarketScreener
FDA Authorizes ProSense Cryoablation System for Early-Stage Breast Cancer in Older Women - Medical Dialogues
IceCure Medical (NASDAQ:ICCM) Price Target Raised to $2.50 - MarketBeat
HC Wainwright & Co. Maintains IceCure Medical (ICCM) Buy Recommendation - Nasdaq
IceCure Medical stock price target raised to $2.50 from $2.00 at H.C. Wainwright - Investing.com
IceCure Medical price target raised to $2.50 from $2 at H.C. Wainwright - TipRanks
ICCM: HC Wainwright & Co. Boosts Price Target to $2.50, Maintains Buy Rating | ICCM Stock News - GuruFocus
IceCure ProSense Cryoablation Receives FDA Marketing Authorization for Treating Low-Risk Breast Cancer in Women Aged 70+ - Imaging Technology News
Icecure gets FDA nod for Prosense cryoablation in breast cancer - BioWorld MedTech
ICCM Shares Rise as FDA Clears ProSense for Breast Cancer Treatment - Yahoo Finance
Transcript : IceCure Medical LtdSpecial Call - MarketScreener
What MACD and RSI say about IceCure Medical Ltd2025 Trading Volume Trends & Accurate Entry/Exit Alerts - newser.com
Chart based exit strategy for IceCure Medical LtdJuly 2025 Rallies & Safe Swing Trade Setup Alerts - newser.com
IceCure Medical Ltd’s volatility index tracking explained2025 Valuation Update & Growth-Oriented Investment Plans - newser.com
IceCure Medical Ltd stock prediction for this weekMarket Performance Recap & Reliable Breakout Forecasts - newser.com
What drives EcoSynthetix Inc 0Y8 stock priceStock Split Announcements & Rapid Wealth Building Tips - earlytimes.in
IceCure Medical Ltd Stock Analysis and ForecastPrice-to-Book Ratio Updates & Your Free Entry to Smart Investing Starts Here - earlytimes.in
IceCure Receives FDA Marketing Authorization for ProSense(R) Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above - MarketScreener
Using portfolio simulators with IceCure Medical Ltd includedJuly 2025 Retail & Safe Capital Investment Plans - newser.com
Key metrics from IceCure Medical Ltd’s quarterly dataQuarterly Trade Summary & Step-by-Step Trade Execution Guides - newser.com
Developing predictive dashboards with IceCure Medical Ltd data2025 AllTime Highs & Real-Time Chart Breakout Alerts - newser.com
Is IceCure Medical Ltd stock attractive for growth ETFsPortfolio Gains Summary & Fast Exit Strategy with Risk Control - newser.com
IceCure Medical Ltd. (NASDAQ:ICCM) Short Interest Down 49.8% in September - MarketBeat
IceCure Medical Surges on FDA Authorization for Breast Cancer Treatment - StocksToTrade
IceCure Medical Ltd. (NASDAQ:ICCM) Receives Average Rating of "Buy" from Analysts - MarketBeat
IceCure Medical Ltd. Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above - MarketScreener
FDA approves IceCure cryoablation for breast cancer - MassDevice
IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above - Lelezard
IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care - Lelezard
ICCM Gains FDA Approval for ProSense Cryoablation System in Cert - GuruFocus
IceCure Receives FDA Marketing Authorization for ProSense® Cryoa - GuruFocus
Icecure Medical Ltd Azioni (ICCM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.23%
0.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):